A2Z Cust2Mate Announces Timing of Third Quarter 2026 Earnings Release and Conference Call

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) will release Q3 2026 earnings on November 11, 2026, after market close, followed by a conference call. The company specializes in smart retail technology, including AI-powered Smart Carts and retail media solutions. Investors can access the call via phone or webcast.

Original reporting
Published Oct 29, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AZ
Neutral
medium confidence
Mentioned
$AZ
Relevance
4/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$AZNeutralMed
01

Why it matters

This sets a clear catalyst for earnings-related volatility and expectation-setting, but it does not provide new operating metrics or guidance in the release itself.

02

Market read

Useful for building an earnings-calendar trade plan for AZ, including pre-positioning and risk management around the after-hours report and call.

03

What to watch

Traders may still need to monitor any concurrent disclosures (8-K filings, investor presentation updates, or changes in consensus estimates) that could emerge between now and Nov. 11, which are not covered here.

Relevance 4/10Novelty 5/10Timing: ahead of the Nov. 11 after-market-close Q3 2026 earnings release and 5:00 PM ET call

Background

The company announced the after-market-close timing for its Q3 2026 results and the same-day conference call details.

Company-level read

Ticker impact

$AZNeutralMedium confidence
Context

A2Z Cust2Mate (NASDAQ: AZ) scheduled its Q3 2026 results for Nov. 11, 2026 after the close, with a 5:00 PM ET call.

Expected impact

Likely increased pre-earnings positioning and after-hours volatility as traders align expectations ahead of the Nov. 11 results.

Evidence & confidence

The article provides a concrete, time-specific catalyst (earnings release and conference call schedule) but no new financial guidance, numbers, or deal/regulatory developments.

Market effects

Limited sector read-through; this is a company-specific earnings timing update rather than a sector-wide signal.

No clear regional spillover beyond US small/mid-cap earnings calendar effects.

Minimal global relevance; the event is localized to the company’s US-listed earnings schedule.

Counterpoint

Because the release timing is routine and the article contains no new financial targets or performance data, the immediate impact on AZ’s valuation may be modest until guidance or results are disclosed.

Key entities

  • A2Z Cust2Mate Solutions Corp.

    NASDAQ-listed smart retail technology company announcing Q3 2026 earnings release timing and conference call schedule.

Related articles

$AZMed

A2Z CUST2MATE SOLUTIONS CORP. (AZ): Financial results for FY2025

A2Z CUST2MATE SOLUTIONS CORP. (AZ) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 A2Z Cust2Mate Completes Acquisition of In-Store Retail Media Business Hedia ● Strategic acquisition adds an established retail media business with approximately $20 million in annual revenues, advertiser relationships and campaign execution capabilities to Cust2Mate

$AZMedAI 8/10

A2Z Reports Second Quarter 2026 Revenue of $5.9 Million

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) reported Q2 2026 revenue of $5.9 million, up from $1.2 million, with Smart Cart revenue of $4.41 million. Gross profit rose to $2.5 million and gross margin to 42.6%. Net loss was $7.3 million. The company cited a $30 million credit line with Bank Leumi and expects $25 million in H2 smart cart revenue.

$AZMedAI 8/10

Allianz enters deal to acquire UOB asset management arm

Allianz Global Investors agreed to acquire UOB Asset Management for S$555m (US$432.7m), covering UOBAM operations in eight Asian markets. UOB and AGI will also form a distribution partnership. UOB expects a pre-tax gain of about S$330m and a CET ratio lift of 14 bps, subject to regulatory approval, with closing in 2027.

$AZMedAI 8/10

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI said it licensed Alphamab’s bispecific ADC JSKN016 for solid tumors outside Greater China in a deal worth up to $2.2 billion, including $125 million upfront, up to $2.09 billion in milestones and royalties. JSKN016 targets TROP2 and HER3 and is in Phase 3 for TNBC. Pathos also partnered with AstraZeneca on AZD4241, an ER-targeting PROTAC in preclinical testing for HR-positive, HER2-negative breast cancer.